Compare PETS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PETS | SCYX |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 44.4M |
| IPO Year | 2003 | 2014 |
| Metric | PETS | SCYX |
|---|---|---|
| Price | $1.53 | $4.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 101.9K | 56.1K |
| Earning Date | 06-09-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $273,800,000.00 | $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | $608.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.55 | $0.57 |
| 52 Week High | $4.10 | $6.09 |
| Indicator | PETS | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 26.26 | 43.02 |
| Support Level | N/A | $4.08 |
| Resistance Level | $1.91 | $5.56 |
| Average True Range (ATR) | 0.05 | 0.37 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 0.00 | 26.77 |
PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.